Nalbuphine for Idiopathic Pulmonary Fibrosis
(OCEAN-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.
Who Is on the Research Team?
Chief Development Officer
Principal Investigator
Trevi Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for adults diagnosed with idiopathic pulmonary fibrosis (IPF) who have a persistent, chronic cough. People with other major lung diseases or health issues that could interfere with the study may not be able to join.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Nalbuphine Extended-Release (NAL ER)
Trial Overview
The study tests whether extended-release nalbuphine (NAL ER) tablets can safely and effectively reduce chronic cough in people with IPF, compared to a placebo. Participants are randomly assigned to receive either NAL ER or placebo.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving NAL ER 54 milligrams (mg) twice daily (BID) for 12 weeks.
Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving a matching placebo BID for 12 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Trevi Therapeutics
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.